LaurenH Posted August 27, 2018 Posted August 27, 2018 Here is the weekly clip report: BioSpace “Drs. Kellie Smith, Jeffrey Thompson, and Edwin Yau receive prestigious LUNGevity 2018 Career Development Awards”https://www.biospace.com/article/releases/drs-kellie-smith-jeffrey-thompson-and-edwin-yau-receive-prestigious-lungevity-2018-career-development-awards/ Cure Today “FDA Grants Full Approval for Keytruda Combination in Lung Cancer”https://www.curetoday.com/articles/fda-grants-full-approval-for-keytruda-combination-in-lung-cancer Immuno-Oncology News “FDA Approves Opdivo for Certain Patients with Advanced Non-Small Cell Lung Cancer”https://immuno-oncologynews.com/2018/08/21/immunotherapy-opdivo-fda-approved-some-small-cell-lung-cancer-patients/ OncLive “Dr. Pacheco on Second-LineTherapy for ALK+NSCLC”https://www.onclive.com/onclive-tv/dr-pacheco-on-secondline-therapy-for-alk-nsclc Radiology Business “Fox Chase Cancer Center receives $673K from U.S. Department of Defense to improve lung cancer screening”https://www.radiologybusiness.com/topics/healthcare-economics/lung-cancer-screening-grant-fox-chase-cancer-center OncLive “Dr. Hall on Combination Approaches in Advanced NSCLC”https://www.onclive.com/onclive-tv/dr-hall-on-combination-approaches-in-advanced-nsclc OncLive “Dr. Camidge on the KEYNOTE-024 Trial in NSCLC”https://www.onclive.com/onclive-tv/dr-camidge-on-the-keynote024-trial-in-nsclc Healio “FDA approves cobas EGFR Mutation Test for use with Iressa in lung cancer”https://www.healio.com/hematology-oncology/lung-cancer/news/online/{6d6095e8-01bc-426f-8a15-f8116e28847a}/fda-approves-cobas-egfr-mutation-test-for-use-with-iressa-in-lung-cancer Mayo Clinic News Network “Q&A: Lung cancer symptoms and prevention”https://medicalxpress.com/news/2018-08-qa-lung-cancer-symptoms.html OncLive “Dr. Naidoo on Managing Immune-Related Adverse Events in NSCLC”https://www.onclive.com/onclive-tv/dr-naidoo-on-managing-immunerelated-adverse-events-in-nsclc
Recommended Posts
Archived
This topic is now archived and is closed to further replies.